Payer Support For Express Scripts’ “Transition” From Walgreens Shows Depth Of Interest In Drug Benefit Savings, PBM Says
This article was originally published in The Pink Sheet Daily
Executive Summary
During Express Scripts’ earnings call Feb. 23, CEO George Paz said the pharmacy benefit manager’s clients are willing to tolerate the potential inconvenience of a smaller pharmacy network, without Walgreens, because it can save them real money.
You may also be interested in...
Express Scripts Dispute With Walgreens Spotlights PBMs’ Thirst For Deeper Discounts
The contracting dispute between the drug chain and PBM may also presage tougher negotiations ahead for biopharmaceutical companies, particularly if Express Scripts is successful in its bid to acquire rival PBM Medco.
Express Scripts/Medco Merger Faces Longer Odds After FTC's Second Request
Following the Federal Trade Commission’s second request for additional information about Express Scripts Inc.'s proposed acquisition of Medco Health Solutions Inc., it is now statistically likely that the deal will be blocked or subject to a divestiture.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.